

Wojciech G Lesniak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7532336/publications.pdf>

Version: 2024-02-01

32
papers

2,191
citations

331670

21
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

3903
citing authors

#	ARTICLE	IF	CITATIONS
1	An Evaluation of CXCR4 Targeting with PAMAM Dendrimer Conjugates for Oncologic Applications. <i>Pharmaceutics</i> , 2022, 14, 655.	4.5	4
2	Hyperosmolar bloodâ€“brain barrier opening using intra-arterial injection of hyperosmotic mannitol in mice under real-time MRI guidance. <i>Nature Protocols</i> , 2022, 17, 76-94.	12.0	26
3	Dual contrast agents for fluorescence and photoacoustic imaging: evaluation in a murine model of prostate cancer. <i>Nanoscale</i> , 2021, 13, 9217-9228.	5.6	19
4	First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3122-3128.	6.4	6
5	Dual-Modality PETâ€“SPECT Image-Guided Pretargeting Delivery in HER2(+) Breast Cancer Models. <i>Biomacromolecules</i> , 2021, 22, 4606-4617.	5.4	7
6	Measurement of PET Quantitative Bias In Vivo. <i>Journal of Nuclear Medicine</i> , 2021, 62, 732-737.	5.0	3
7	High Availability of the $\alpha 7$ -Nicotinic Acetylcholine Receptor in Brains of Individuals with Mild Cognitive Impairment: A Pilot Study Using ^{18}F -ASEM PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 423-426.	5.0	22
8	Optimization of osmotic blood-brain barrier opening to enable intravital microscopy studies on drug delivery in mouse cortex. <i>Journal of Controlled Release</i> , 2020, 317, 312-321.	9.9	35
9	^{11}C -PABA as a PET Radiotracer for Functional Renal Imaging: Preclinical and First-in-Human Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1665-1671.	5.0	11
10	PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP. <i>EJNMMI Research</i> , 2020, 10, 67.	2.5	10
11	PET imaging of distinct brain uptake of a nanobody and similarly-sized PAMAM dendrimers after intra-arterial administration. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1940-1951.	6.4	33
12	Development of [^{18}F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. <i>Molecular Imaging</i> , 2019, 18, 153601211985218.	1.4	52
13	Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2019, 16, 2590-2604.	4.6	29
14	PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1686-1691.	7.1	140
15	A Distinct Advantage to Intraarterial Delivery of ^{89}Zr -Bevacizumab in PET Imaging of Mice With and Without Osmotic Opening of the Bloodâ€“Brain Barrier. <i>Journal of Nuclear Medicine</i> , 2019, 60, 617-622.	5.0	49
16	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. <i>Journal of Clinical Investigation</i> , 2019, 129, 616-630.	8.2	94
17	A side-by-side evaluation of [18F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography. <i>Oncotarget</i> , 2019, 10, 5731-5744.	1.8	3
18	^{18}F -XTRA PET for Enhanced Imaging of the Extrathalamic $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1603-1608.	5.0	15

#	ARTICLE	IF	CITATIONS
19	The distribution of the alpha7 nicotinic acetylcholine receptor in healthy aging: An in vivo positron emission tomography study with [18F]ASEM. <i>NeuroImage</i> , 2018, 165, 118-124.	4.2	27
20	Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. <i>Journal of Neuroinflammation</i> , 2018, 15, 346.	7.2	46
21	Rapid PD-L1 detection in tumors with PET using a highly specific peptide. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 258-263.	2.1	132
22	Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy. <i>Molecular Imaging</i> , 2017, 16, 153601211771845.	1.4	47
23	In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent. <i>Chemistry - A European Journal</i> , 2017, 23, 14469-14475.	3.3	25
24	Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. <i>Science</i> , 2017, 357, 503-507.	12.6	813
25	A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. <i>Oncotarget</i> , 2016, 7, 12344-12358.	1.8	32
26	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. <i>Oncotarget</i> , 2016, 7, 10215-10227.	1.8	158
27	PD-L1 Detection in Tumors Using [⁶⁴ Cu]Atezolizumab with PET. <i>Bioconjugate Chemistry</i> , 2016, 27, 2103-2110.	3.6	128
28	Structural Characterization and in Vivo Evaluation of ¹²⁵ I-Hairpin Peptidomimetics as Specific CXCR4 Imaging Agents. <i>Molecular Pharmaceutics</i> , 2015, 12, 941-953.	4.6	13
29	Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). <i>Nuclear Medicine and Biology</i> , 2014, 41, 552-561.	0.6	25
30	Fetal uptake of intra-amniotically delivered dendrimers in a mouse model of intrauterine inflammation and preterm birth. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1343-1351.	3.3	30
31	Concurrent quantification of tryptophan and its major metabolites. <i>Analytical Biochemistry</i> , 2013, 443, 222-231.	2.4	51
32	Biodistribution of Fluorescently Labeled PAMAM Dendrimers in Neonatal Rabbits: Effect of Neuroinflammation. <i>Molecular Pharmaceutics</i> , 2013, 10, 4560-4571.	4.6	101